Impact of initial serum ferritin on early post-HSCT complications: a single-center study

Shaheen, Mostafa; Ivanova, Maria; Моисеев, И. С.; Afanasyev, Boris; Бондарчук, С. В.

doi:10.18620/1866-8836-2016-5-2-40-49

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An additional adverse factor for patients with refractory disease was iron overload due to multiple blood transfusions. In accordance with our previous fi ndings, we observed that the baseline increase of serum ferritin contents is associated with higher risk of febrile episodes, infectious conditions, and slower recovery of myeloid cells [34].…”

Section: Clinical Studiessupporting

confidence: 93%

Haploidentical stem cell transplantation in adults for the treatment of hematologic diseases: results of a single center (CIC725)

Beinarovich¹,

Babenko²,

Moiseev³

et al. 2019

CTT

Self Cite

View full text Add to dashboard Cite

Allogeneic HSCT (allo-HSCT) is potentially curative option for a wide variety of malignant and nonmalignant disorders of hematopoiesis. For patients who lack an HLA-matched sibling, HLA-haploidentical related donors (haplo-HSCT) can be considered as alternative sources of donor graft s. Th e benefi ts of haplo-HSCT include immediate donor availability for patients who are in urgent need of the transplant. Besides, an availability of a related donor makes post-transplant donor-derived cellular therapy more easily accessible. In addition, the greater HLA mismatch associated with haploidentical HSCT (haplo-HSCT) may potentiate graft-versus-tumor (GVT) eff ects. Th e aim of our study was to summarize our single-center experience of haplo-HSCT performed with non-manipulated graft s in adult patients with different malignant diseases. Th e study included a total of 119 patients with diff erent hematological disorders subjected to haplo-HSCT. At the time of analysis, median follow-up was 371 days (1-2219). Most frequent diagnosis in transplanted patients was acute leukemia. 67 (56%) patients received haplo-HSCT as salvage therapy. Overall survival with an observation term of 2 years was 40.3% for the general group. In particular, the two-year OS in patients transplanted in remissions of ALL and AML was 57% and 46% respectively as compared to 22% and 15% for the patients transplanted in adverse disease status). Two-year event-free survival (EFS) and GVHD-free/relapse-free survival (GRFS) group proved to be 35.7% and 21% respectively. Th e cumulative incidence of acute GVHD grade II-IV and severe aGVHD grade III-IV was 19% and 10% respectively. Th e cumulative incidence of chronic GVHD (cGVHD) was 16%. Th e cumulative incidence of relapse was 21%. Th e overall transplant-associated mortality was 43% in the studied group. In conclusion, our results show that unmanipulated haplo-HSCT is reasonable treatment option for adult patients with diff erent malignant disorders of hematopoiesis. However, such problems as higher rate graft failure, increased nonrelapse mortality (NRM) and post-transplant relapses remain extremely relevant.

show abstract

Section: Clinical Studiessupporting

confidence: 93%

Haploidentical stem cell transplantation in adults for the treatment of hematologic diseases: results of a single center (CIC725)

Beinarovich¹,

Babenko²,

Moiseev³

et al. 2019

CTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…The potential causes for early mortality in this group are relatively well discussed in the literature. They include primary graft failure [21], iron overload which results in higher incidence of liver veno-occlusive disease [22] and infectious complications [23]. It should be noted that, according to our data, the rate of primary graft failure is 10% being considered relatively high.…”

Section: Clinical Studiesmentioning

confidence: 70%

Application of standard and novel prognostic systems in patients with myelodys- plastic syndrome undergoing allogeneic hematopoietic stem cell transplantation

Morozova¹,

Barabanshikova²,

Tsvetkov³

et al. 2019

CTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Повышенный исходный уровень ферритина, будучи потенциальным отражением многих процессов (активности заболевания, множественных трансфузий, инфекций), представляется фактором риска смерти вне рецидивов и прогноза ОВ у пациентов после аллоТГСК [30,31]. В данной когорте уровень ферритина был проанализирован в проспективной части исследования и имел значение в отношении развития тГФТ.…”

Section: Discussionunclassified

Severe "Poor Graft Function" after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients: Incidence, Risk Factors, and Outcomes

Rudakova¹,

Клімова²,

Golubovskaya³

et al. 2019

Клиническая онкогематология

View full text Add to dashboard Cite

Цель. Оценить в соответствии со строгими критериями частоту возникновения, предтрансплантационные факторы риска и исходы тяжелой гипофункции трансплантата (тГФТ) после аллогенной трансплантации гемопоэтических стволовых клеток (аллоТГСК) у взрослых. Материалы и методы. В исследование включено 710 взрослых пациентов (медиана возраста 31 год, диапазон 18-70 лет; 55 % мужчин, 45 % женщин) с различными гематологическими заболеваниями и документированным приживлением трансплантата после аллоТГСК от совместимого сиблинга (20 %), неродственного (67 %) и гаплоидентичного (13 %) доноров в период с 2008 по 2016 г. Миелоаблативное кондиционирование и режимы со сниженной интенсивностью использовались у 30 и 70 % больных соответственно. Критерии тГФТ: цитопения в 2 линиях и более (тромбоциты < 20 × 10 9 /л, абсолютное число нейтрофилов < 0,5 × 10 9 /л, гемоглобин < 70 г/л в любой момент времени после документированного приживления), полный или стабильный смешанный донорский химеризм > 90 % и отсутствие признаков рецидива, отторжения и тяжелой острой реакции «трансплантат против хозяина». Анализировались следующие факторы: возраст, пол, диагноз, наличие/отсутствие ремиссии при острых лейкозах, уровень ферритина крови, тип донора, HLA-совместимость, совместимость по группе крови и полу, источник трансплантата, число трансплантированных клеток CD34+, режим кондиционирования. Многофакторный анализ включал параметры со значением p < 0,05 в однофакторном анализе. Результаты. тГФТ после аллоТГСК диагностирована у 103 пациентов с 2-летней кумулятивной частотой 15 % (95%-й доверительный интервал [95% ДИ] 12-18 %).

show abstract

Impact of initial serum ferritin on early post-HSCT complications: a single-center study

Cited by 4 publications

References 22 publications

Haploidentical stem cell transplantation in adults for the treatment of hematologic diseases: results of a single center (CIC725)

Haploidentical stem cell transplantation in adults for the treatment of hematologic diseases: results of a single center (CIC725)

Application of standard and novel prognostic systems in patients with myelodys- plastic syndrome undergoing allogeneic hematopoietic stem cell transplantation

Severe "Poor Graft Function" after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients: Incidence, Risk Factors, and Outcomes

Contact Info

Product

Resources

About